Table 4.
Summary of biopsy proven acute rejection in clinical trials
|
Ref.
|
IA
|
IB
|
IIA
|
IIB
|
III
|
Mixed
|
|
|||||||
|
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
| Ferguson et al[33], 2011 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 1 | 0 | 0 | ||||
| de Graav et al[34], 2017 | 0 | 0 | 1 | 1 | 2 | 1 | 6 | 0 | 1 | 0 | 1 | 0 | ||
| Newell et al[35], 2017 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | ||
| Clinicaltrial.gov 1856257[36], 2017 | 3 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | ||
BPAR: Biopsy proven acute rejection; Gp: Group; AMR: Antibody mediated rejection.